The world's most promising therapies sit in specialist clinics that are ready to scale. SwissMedX is the layer that connects them — bringing patients in, helping clinicians grow.
Patients, clinicians, and strategic players all pay the cost of fragmentation — no one owns the journey.
No trusted navigation across therapies and countries. No comparable pricing or evidence baseline. No outcome feedback after the fact.
Manual, referral-based, non-scalable demand. No agentic intake, triage, or compliance infrastructure. No premium brand to wrap the service.
A fragmented longevity marketplace. No scalable distribution for new therapies. No population-level outcome data to underwrite future programmes.
No actor owns the journey — this is what SwissMedX addresses.
Four structural forces converge in 2026. The window for SwissMedX is open now.
Longevity is the fastest-growing cash-pay segment in health. High-net-worth and mainstream cohorts converge around the same motivations.
High-value therapies exist globally but operate at clinic-scale. Fragmented across countries and modalities, with no horizontal scaling layer.
For the first time, agentic commerce is feasible in healthcare — evidence-matched, personalised, outcome-tracked navigation that runs software-native.
Switzerland remains one of the last globally legible premium signals in health — read as quality, governance, and credibility.
Trust capital flows in one direction — from the Platform outward. Each product carries its own status, scope, and operating discipline.
A deterministic, evidence-based recommendation engine for health goals, biomarkers, conditions, and interventions. The trust anchor of the brand.
A curated commerce layer covering supplements, devices, lab panels, services, therapies, and bundled longevity programmes.
A high-touch service coordinating premium clients through clinic partners — from treatment coordination to multi-day, full-service experiences.
The structural commitments that make SwissMedX more than a wellness-app-plus-shop.
Goal-oriented discovery across the longevity space. Products, services, and therapies combine into coherent journeys, not isolated transactions.
Accredited partners. Certifications. Audited recommendations. Evidence inclusion. Swiss-brand quality as a structural commitment, not a marketing line.
Personalised navigation through the SwissMedX Engine. Users are guided with recommendations, triage, and routing to the right partner at the right moment.
Follow-up, monitoring, reassessment. Outcomes feed back into the protocols and improve them over time.
Competitors operate in one or two layers. SwissMedX operates in all four.
Three profiles. One Platform. Same evidence.
You already track biomarkers, read primary sources, and run your own protocol. What you need is a single auditable map — one place where the supplements, devices, lab panels, and interventions you are testing fit into one coherent picture, with the evidence visible at every step.
You are managing a condition that your GP cannot fully orchestrate — perimenopause, metabolic dysfunction, autoimmune complexity, long-term recovery. What you need is structured navigation across what to consider next: which biomarkers, which specialists, which therapies, in which order, with what evidence behind each.
You are building a decade-long practice, not chasing a quarterly trend. What you need is a recommendation engine that updates with your data, traces back to its sources, and treats your protocol as a living document rather than a one-time output.
The positioning differentiator. Switzerland as one of the last globally legible premium signals in health. Not a flag in the marketing; a structural choice.
The operational differentiator. Triple Mapping of empirical evidence (your data), direct outcome evidence (clinical studies), and mechanistic evidence (biological pathways). Every recommendation reproducible from its source.
By architectural commitment, not by policy. The trust anchor is not allowed to be commercially contaminated.
The operating system for trusted longevity journeys.
A limited cohort of health optimisers, engaged patients, and longevity-oriented users.
The investor narrative goes beyond the platform and highlights the whole business model.
Open the pitch deck →